Payment overview · 2025
General Payments
$129.49
7 reported records · 5 companies
Healthcare provider profile · identity verified
Basil Pittenger, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COOS BAY, OR · NPI 1225013485
Verified facts
What the public records show
CMS Open Payments records show Basil Pittenger, MD received $129.49 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.04 | 37.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.12 | 23.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.85 | 14.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.96 | 13.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15.52 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.50 | 6 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $48.04 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
281 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1003 | 262 |
| Amlodipine Besylate | Amlodipine Besylate | 402 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 94 |
| Losartan Potassium | Losartan Potassium | 343 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 84 |
| Furosemide | Furosemide | 290 | 74 |
| Eliquis | Apixaban | 281 | 59 |
| Lisinopril | Lisinopril | 251 | 65 |
| Gabapentin | Gabapentin | 248 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 39 |
| Omeprazole | Omeprazole | 210 | 48 |
| Carvedilol | Carvedilol | 206 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 40 |
| Trazodone Hcl | Trazodone Hcl | 185 | 43 |
| Alendronate Sodium | Alendronate Sodium | 177 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 48 |
| Potassium Chloride | Potassium Chloride | 175 | 44 |
| Metformin Hcl | Metformin Hcl | 170 | 48 |
| Buspirone Hcl | Buspirone Hcl | 159 | 33 |
| Spironolactone | Spironolactone | 155 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 41 |
| Farxiga | Dapagliflozin Propanediol | 123 | 26 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 120 | 114 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 26 |
| Memantine Hcl | Memantine Hcl | 100 | 20 |
| Allopurinol | Allopurinol | 99 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 31 |
| Baclofen | Baclofen | 90 | 23 |
| Warfarin Sodium | Warfarin Sodium | 89 | 24 |
| Famotidine | Famotidine | 80 | 23 |
| Meloxicam | Meloxicam | 79 | 16 |
| Celecoxib | Celecoxib | 78 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 23 |
| Metformin Hcl Er | Metformin Hcl | 78 | 21 |
| Ozempic | Semaglutide | 75 | suppressed |
| Jardiance | Empagliflozin | 73 | 17 |
| Sertraline Hcl | Sertraline Hcl | 67 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 22 |
| Valsartan | Valsartan | 65 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 64 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 17 |
| Donepezil Hcl | Donepezil Hcl | 59 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 12 |
| Simvastatin | Simvastatin | 54 | 15 |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Irbesartan | Irbesartan | 49 | suppressed |
| Pregabalin | Pregabalin | 48 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 46 | 13 |
| Tramadol Hcl | Tramadol Hcl | 46 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 11 |
| Ondansetron Odt | Ondansetron | 40 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Eplerenone | Eplerenone | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 12 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Victoza 3-Pak | Liraglutide | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 16 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Zafirlukast | Zafirlukast | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 17 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trandolapril | Trandolapril | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.49 · 7 records | Exact Sciences Corporation | AMVUTTRA, BREZTRI, CAMZYOS, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FARXIGA, The Cologuard Plus Collection Kit | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error